The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2021 | MRD monitoring in CLL and implications for clinical practice
Paolo Ghia, MD, Università Vita-Salute San Raffaele, Milan, gives an overview of the role of measurable residual disease (MRD) monitoring in the management of chronic lymphocytic leukemia (CLL), highlighting the incorporation of MRD assessment into clinical trials. For example, the Phase II CAPTIVATE trial (NCT02910583) has an MRD-guided cohort in which patients who achieved undetectable MRD were randomized to either placebo or ibrutinib. Dr Ghia reports that these cohorts demonstrated similar event-free survival at two year, indicating that ibrutinib therapy may be stopped based on undetectable MRD. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
